Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 11/20 | 0.75 |
| ▸ | PDE3A | Q14432 | 11/20 | 0.75 |
| ▸ | ACHE | P22303 | 7/20 | 0.49 |
| ▸ | BCHE | P06276 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1570768 | 0.86 | PDE3B (1.00) | PDE3BPDE3AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7316421 | 0.84 | PDE3B (0.97) | PDE3BPDE3AMEN1USP2ALDH1A1 | |
| SCHEMBL10376168 | 0.74 | PDE3B (0.55) | PDE3BPDE3AACHEBCHEMEN1 | |
| Hydrochloric Acid SCHEMBL11522942 | 0.73 | PDE3B (0.54) | PDE3BPDE3AACHEBCHEMEN1 | |
| SCHEMBL6488560 | 0.72 | PDE3B (0.42) | PDE3BPDE3AMEN1KMT2A | |
| SCHEMBL11983526 | 0.67 | PDE3B (0.54) | PDE3BPDE3AACHEBCHEMEN1 | |
| SCHEMBL11983504 | 0.67 | PDE3B (0.54) | PDE3BPDE3AACHEBCHEMEN1 | |
| SCHEMBL29416837 | 0.66 | ACHE (1.00) | PDE3BPDE3AACHEBCHEMEN1 | |
| SCHEMBL3387188 | 0.66 | ACHE (1.00) | PDE3BPDE3AACHEBCHEMEN1 | |
| SCHEMBL10678336 | 0.66 | PDE3B (1.00) | PDE3BPDE3AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180153810-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR INC (US) | 2018-06-07 | — | — | US | disclosed |
| US-9750698-B2 | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor | BIOVASCULAR, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170112767-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. | 2017-04-27 | — | — | US | disclosed |
| US-9381198-B2 | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor | BIOVASCULAR, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20160051552-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. | 2016-02-25 | — | — | US | disclosed |
| US-9040483-B2 | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor | BIOVASCULAR, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20130022671-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. | 2013-01-24 | — | — | US | disclosed |
| US-20100008913-A1 | Methods and compositions for treating platelet-related disorders | HANSON, STEPHEN R. | 2010-01-14 | — | — | US | disclosed |
| US-20090324710-A1 | Controlled release dosage forms for platelet inhibitor such as anagrelide, optionally in combination with other drugs; prevention of vaso-occlusive events, such as embolism | BIOVASCULAR, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20080113024-A1 | Methods and compositions for treating platelet-related disorders | COMERICA BANK | 2008-05-15 | — | — | US | disclosed |
| US-20050228001-A1 | Methods and compositions for treating platelet-related disorders | COMERICA BANK | 2005-10-13 | — | — | US | disclosed |
| EP-0722936-B1 | FUSED PYRIDAZINE COMPOUND | EISAI CO LTD (JP) | 2004-05-19 | — | — | EP | disclosed |
| US-6380193-B1 | POLY(ADENOSINE 5'-DIPHOSPHO-RIBOSE)POLYMERASE; TREATMENT OR PREVENTION OF NEUROLOGICAL AND NEURODEGENERATIVE DISEASES, VASCULAR STROKE | GUILFORD PHARMACEUTICALS INC. | 2002-04-30 | — | — | US | disclosed |
| US-6218392-B1 | FOR THERAPY AND PROPHYLAXIS OF ISCHEMIC HEART DISEASES SUCH AS ANGINA PECTORIS, MYOCARDIAL INFARCT AND CHRONIC AND ACUTE CARDIAC FAILURE, PULMONARY HYPERTENSION, ARTERIOSCLEROSIS AND BRONCHIAL ASTHMA | EISAI CO., LTD. (JP) | 2001-04-17 | — | — | US | disclosed |
| US-6121278-A | POLY(ADENOSINE 5'-DIPHOSPHO-RIBOSE)POLYMERASE (PARP) ENZYME INHIBITOR FOR TREATMENT OF NEUROLOGICAL DISORDERS, ARTHRITIS, DIABETES, INFLAMMATION, CARDIOVASCULAR DISORDERS, SEPTIC SHOCK, CANCER | GUILFORD PHARMACEUTICALS, INC. (US) | 2000-09-19 | — | — | US | disclosed |
| US-5849741-A | Fused pyridazine compounds | EISAI CO., LTD. (JP) | 1998-12-15 | — | — | US | disclosed |
| EP-0722936-A1 | FUSED PYRIDAZINE COMPOUND | Eisai Co., Ltd. (JP) | 1996-07-24 | — | — | EP | disclosed |
| US-RE31617-E | ANTICOAGULANTS; HYPOTENSIVE AND BRONCHODILATOR AGENTS | BRISTOL-MYERS COMPANY (US) | 1984-06-26 | — | — | US | disclosed |
| US-3932407-A | BRONCHODILATORS, HYPOTENSIVE AGENTS, ANTICOAGULANTS | BRISTOL-MYERS COMPANY (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324710-A1 | Controlled release dosage forms for platelet inhibitor such as anagrelide, optionally in combination with other drugs; prevention of vaso-occlusive events, such as embolism | PF4, PLAT, VASP | PDE3B 64/4885PDE3A 50/4885ACHE 655/4885 |
| US-20130022671-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | SERPINC1, PLAT, MPL | PDE3B 69/4885PDE3A 60/4885ACHE 1109/4885 |
| US-20160051552-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | SERPINC1, PLAT, MPL | PDE3B 69/4885PDE3A 60/4885ACHE 1109/4885 |
| US-20180153810-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | SERPINC1, PLAT, MPL | PDE3B 69/4885PDE3A 60/4885ACHE 1109/4885 |
| US-20170112767-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | SERPINC1, PLAT, MPL | PDE3B 69/4885PDE3A 60/4885ACHE 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.